Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
Ipsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day One Biopharmaceuticals for its paediatric glioma therapy Ojemda (tovorafenib). Ipsen will make an upfront payment of $111m, …